Iovance’s TIL therapy makes early headway in lung cancer; Antios and Arbutus join hands on HBV combo treatment

Iovance has posted a first look at its tumor infiltrating lymphocytes as a treatment for non-small cell lung cancer, paving the way for a pivotal study.

Among 28 patients enrolled in Cohort 3B of the IOV-COM-202 basket study — 24 of whom were evaluable — investigators recorded an overall response...

Click to view original post